Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Debt (2019 - 2026)

Biodesix filings provide 8 years of Total Debt readings, the most recent being $46.5 million for Q1 2026.

  • On a quarterly basis, Total Debt rose 26.69% to $46.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $46.5 million, a 26.69% increase, with the full-year FY2025 number at $47.4 million, up 30.31% from a year prior.
  • Total Debt hit $46.5 million in Q1 2026 for Biodesix, down from $47.4 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $57.1 million in Q4 2023 to a low of $14.2 million in Q3 2022.
  • Median Total Debt over the past 5 years was $39.2 million (2023), compared with a mean of $39.1 million.
  • Biggest five-year swings in Total Debt: tumbled 67.13% in 2022 and later skyrocketed 212.42% in 2023.
  • Biodesix's Total Debt stood at $35.3 million in 2022, then skyrocketed by 61.5% to $57.1 million in 2023, then tumbled by 36.22% to $36.4 million in 2024, then surged by 30.31% to $47.4 million in 2025, then fell by 2.02% to $46.5 million in 2026.
  • The last three reported values for Total Debt were $46.5 million (Q1 2026), $47.4 million (Q4 2025), and $47.1 million (Q3 2025) per Business Quant data.